A Single-Blind Crossover Study of Two Different Slow Release Theophylline Preparations

1988 ◽  
Vol 16 (6) ◽  
pp. 452-458 ◽  
Author(s):  
G. Tatsis ◽  
J. Danos ◽  
M. Gaga ◽  
D. Pantelakis ◽  
M. Veslemes ◽  
...  
Keyword(s):  
Crossover Study ◽  
Adverse Reactions ◽  
Slow Release ◽  
Theophylline Concentration ◽  
Plasma Theophylline ◽  
Days Of Therapy ◽  
The Mean ◽  
Anhydrous Theophylline ◽  
Single Blind ◽  
Blind Crossover Study

In a single-blind crossover study, two slow release theophylline preparations were evaluated in 18 patients with chronic bronchitis or asthma without cardiac, renal or liver disease. After randomization into two groups, patients were treated, in a crossover study design, with 600 mg choline theophyllinate or 300 mg anhydrous theophylline administered orally every 12 h for 7 days. A 2-day washout period separated the two periods of treatment evaluation. Blood samples in which plasma theophylline concentration was to be measured were taken at 7.30 a.m., 2.00 p.m. and 7.30 p.m. during the last 5 days of therapy with each drug. The mean fluctuation in plasma theophylline concentration was ≤40% in all 18 patients taking choline theophyllinate yet in only 15 (83%) patients administered anhydrous theophylline. Salbutamol inhaler was more frequently required for the relief of bronchospasm when taking anhydrous theophylline than when taking choline theophyllinate (total of 41 vs 25 puffs, respectively, over 7 days). Drug-related adverse reactions occurred in four patients while taking anhydrous theophylline and in one patient while taking choline theophyllinate.

Bioavailability of a New Sustained-Release Anhydrous Theophylline Product

1996 ◽  
Vol 24 (4) ◽  
pp. 331-339 ◽  
Author(s):  
G Tatsis ◽  
G Tsoukalas ◽  
A Haviaras ◽  
A Peristerakis ◽  
V Filaditaki ◽  
...  
Keyword(s):  
Sustained Release ◽  
Adverse Reactions ◽  
Chronic Obstructive Lung Disease ◽  
New Product ◽  
Chronic Obstructive ◽  
Maximum Plasma ◽  
Theophylline Concentration ◽  
Time Curve ◽  
Plasma Theophylline ◽  
Anhydrous Theophylline

The bioavailability of a new sustained-release anhydrous theophylline product (Theophylline Lavipharm®) was evaluated and compared with the bioavailability of a well-established product, Theodur®. Two groups of 12 healthy non-smokers were given single doses of 200 or 300 mg of each product and two groups of 12 patients with asthma or chronic obstructive lung disease were given doses of 200 or 300 mg of each product every 12 h for 5-day periods. The values of the area under the plasma theophylline concentration against time curve (AUC), the maximum plasma theophylline concentration ( Cmax) and the time taken to reach Cmax (Tmax) for the two products did not differ significantly in the healthy groups or in the patients. The minimum and the average plasma theophylline concentrations and the fluctuation index were also calculated for the patients and there were no significant differences between the values for the two products. The new anhydrous theophylline product, Theophylline Lavipharm®, appears to show very similar bioavailability to Theodur®. No adverse reactions to the new product were reported.

scholarly journals Treating primary hypothyroidism with weekly doses of levothyroxine: a randomized, single-blind, crossover study

2012 ◽  
Vol 56 (4) ◽  
pp. 250-258 ◽  
Author(s):  
Andressa Bornschein ◽  
Gilberto Paz-Filho ◽  
Hans Graf ◽  
Gisah A. de Carvalho
Keyword(s):  
Crossover Study ◽  
Primary Hypothyroidism ◽  
Weekly Dose ◽  
Safe Alternative ◽  
Cardiac Symptoms ◽  
Daily Schedule ◽  
Single Blind ◽  
Levothyroxine Treatment ◽  
Randomized Crossover Study ◽  
Blind Crossover Study

OBJECTIVE: Compliance to levothyroxine treatment in hypothyroidism is compromised by daily schedule, and a weekly dose may be an alternative. SUBJECTS AND METHODS: This was a randomized, crossover study. Fourteen females were assigned to daily or weekly doses of LT4. After six weeks, they switched regimens. Thyroid parameters were measured at baseline, and after 42 and 84 days. Echocardiogram and hyperthyroidism symptoms were evaluated before and four hours after LT4 intake. RESULTS: In the weekly dose treatment, fT4 levels were higher after taking LT4, and lower seven days after the last dose; by the 6th week there was a small decrease in T3 levels. TSH remained unchanged and there were no hyperthyroidism symptoms or echocardiographic manifestations. CONCLUSION: Weekly dose leads to transient increases in fT4, without hyperthyroidism or cardiac symptoms. That approach seems to be a safe alternative for the treatment of hypothyroidism.

scholarly journals Acute effects of beer on endothelial function and hemodynamics: A single-blind, crossover study in healthy volunteers

Nutrition ◽  
2013 ◽  
Vol 29 (9) ◽  
pp. 1122-1126 ◽  
Author(s):  
Kalliopi Karatzi ◽  
Victoria G. Rontoyanni ◽  
Athanase D. Protogerou ◽  
Aggeliki Georgoulia ◽  
Konstantinos Xenos ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Crossover Study ◽  
Healthy Volunteers ◽  
Acute Effects ◽  
Single Blind ◽  
Blind Crossover Study

A Trial of Fortagesic and Paramol 118 in Osteoarthritis

1976 ◽  
Vol 4 (6) ◽  
pp. 432-434 ◽  
Author(s):  
C J Andrews ◽  
L Cohen ◽  
R B Crail ◽  
G Douch ◽  
M G Sheldon ◽  
...  
Keyword(s):  
Side Effects ◽  
Crossover Study ◽  
Moderate Pain ◽  
Single Blind ◽  
Blind Crossover Study

Fortagesic was compared with Paramol 118 in a fourteen day single-blind crossover study in patients with moderate pain due to osteoarthritis. Both preparations were shown to be similarly effective. More side-effects were seen with Paramol 118 than with Fortagesic and more patients preferred Fortagesic. These differences were not statistically significant, but it is concluded that Fortagesic is a useful effective analgesic for standard use in moderate pain.

A Comparative Study of the Effectiveness and Safety of Two Non-Steroidal Anti-Inflammatory Agents, Nabumetone and Naproxen in Rheumatoid Arthritis

1982 ◽  
Vol 10 (4) ◽  
pp. 204-208 ◽  
Author(s):  
G Fostiropoulos ◽  
E A P Croydon
Keyword(s):  
Rheumatoid Arthritis ◽  
Comparative Study ◽  
Crossover Study ◽  
Grip Strength ◽  
Analgesic Activity ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Single Blind ◽  
Blind Crossover Study ◽  
Articular Index

A single-blind crossover study of two non-steroidal anti-inflammatory drugs, nabumetone (1000 mg/day) and naproxen (500 mg/day) was performed in thirty patients suffering from definite or classical rheumatoid arthritis. Nabumetone significantly improved the various parameters assessed, while this was not observed with naproxen. The superiority of nabumetone over naproxen appeared for the anti-inflammatory activity (e.g. E.S.R., articular index, P.I.P. joint circumference, grip strength) as well as for the analgesic activity (patient's opinion). The clinical tolerance appeared equally good for both drugs.

scholarly journals Bioequivalence evaluation of two oral formulations of Dexketoprofen-trometamol (solution and tablets) in healthy subjects: Results from a randomized, single-blind, crossover study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jorge González-Canudas ◽  
Luis Jesús García-Aguirre ◽  
Araceli Medina-Nolasco ◽  
María Isabel Ruíz-Olmedo ◽  
Liz Janet Medina Reyes ◽  
...  
Keyword(s):  
Crossover Study ◽  
Healthy Subjects ◽  
Oral Formulations ◽  
Dexketoprofen Trometamol ◽  
Single Blind ◽  
Blind Crossover Study
Sign in / Sign up

Export Citation Format

Share Document